Suzanne A W Fuqua

11PUBLICATIONS
60CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Microelectromechanical systems (MEMS)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 12, 2026
Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.

Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos H Barcenas

|Jan 07, 2026
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.

Sarah K Herzog, Jessica H Stevens, Guowei Gu

|May 23, 2024
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.

Anran Chen, Beom-Jun Kim, Aparna Mitra

|Oct 31, 2023
Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.

Songyeon Ahn, Jun Hyoung Park, Sandra L Grimm

|Oct 08, 2021
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.

Sarah K Herzog, Suzanne A W Fuqua

|Jul 06, 2021
Metastasis: complexity thwarts precision targeting.

Suzanne A W Fuqua

Pageof 2

Frequent Collaborators

4 joint publications

Cristian Coarfa

3 joint publications

Charles E Foulds

2 joint publications

Sebastiano Andò

2 joint publications

Sarah K Herzog